Cepheid (NASDAQ:CPHD) traded down 2.3% during trading on Tuesday . The stock traded as low as $34.01 and last traded at $34.26, with a volume of 275,606 shares changing hands. The stock had previously closed at $35.07.

Several equities research analysts have commented on the stock. Canaccord Genuity reaffirmed a “hold” rating and issued a $32.00 target price on shares of Cepheid in a research note on Wednesday, June 29th. Zacks Investment Research cut shares of Cepheid from a “buy” rating to a “hold” rating in a report on Wednesday, June 29th. TheStreet cut shares of Cepheid from a “hold” rating to a “sell” rating in a report on Monday, June 6th. JPMorgan Chase & Co. upped their price target on shares of Cepheid from $32.00 to $35.00 and gave the company a “neutral” rating in a report on Friday, July 29th. Finally, Morgan Stanley assumed coverage on shares of Cepheid in a report on Wednesday, June 15th. They issued an “equal weight” rating and a $30.00 price target for the company. One analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $40.13.

The firm’s 50-day moving average is $34.79 and its 200 day moving average is $31.80. The company’s market cap is $2.51 billion.

Cepheid (NASDAQ:CPHD) last announced its quarterly earnings results on Thursday, July 28th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.19. The business earned $146 million during the quarter, compared to analysts’ expectations of $145.82 million. The business’s revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.06) EPS. On average, equities research analysts predict that Cepheid will post $0.33 EPS for the current fiscal year.

In other Cepheid news, VP Scott A. Campbell sold 746 shares of the stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $36.71, for a total value of $27,385.66. Following the completion of the transaction, the vice president now owns 10,721 shares in the company, valued at $393,567.91. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.